Overview
TXG market data
Price History
TXG price chart · 1M
- O
- 63.88
- H
- 65.61
- L
- 63.88
- C
- 64.84
- Vol
- 115,829.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $63.88
- Previous Close
- $64.27
- Day High
- $65.61
- Day Low
- $63.88
- 52 Week High
- $66.91
- 52 Week Low
- $19.54
- 7 Day Return
- +1.51%
- 30 Day Return
- +37.90%
- 90 Day Return
- +128.87%
- 1 Year Return
- +220.99%
- Daily Notional Volume
- $7.5M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.35 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.07 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -12.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $11.16 – $66.94 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $7.6B · P/B 2.59 · P/S 12.32.
Company News
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On WednesdayBenzinga · Aug 19, 2026, 2:08 PM
Stephens & Co. Maintains Overweight on 10x Genomics, Raises Price Target to $65Benzinga · Aug 12, 2026, 4:21 PM
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $47Benzinga · Aug 10, 2026, 6:37 PM
10x Genomics shares are trading higher after Canaccord raised its price target on the stock from $50 to $60.Benzinga · Aug 10, 2026, 2:59 PM
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $60Benzinga · Aug 10, 2026, 12:01 PM
Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $50Benzinga · Aug 7, 2026, 8:19 PM
Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $40Benzinga · Aug 7, 2026, 6:18 PM
Precision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with ConfidenceGlobenewswire Inc · Aug 7, 2026, 11:00 AM
10x Genomics Raises FY2026 Sales Guidance from $600.000M-$625.000M to $610.000M-$630.000M vs $613.851M EstBenzinga · Aug 6, 2026, 8:07 PM
10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M EstimateBenzinga · Aug 6, 2026, 8:05 PM